NASDAQ · LABT
Lakewood-Amedex Biotherapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for LABT: Nov 12, 2026
Lakewood-Amedex Biotherapeutics Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $0.81.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.81 | $0.81 | $0.81 | 1 |
| Dec 2026 | $0.76 | $0.76 | $0.76 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews- Fintel · Oct 28, 8:27 PM EDTHC Wainwright & Co. initiates coverage of Lakewood-Amedex Biotherapeutics with Buy ratingFintel reports that on October 28, 2026, HC Wainwright & Co. initiated coverage of Lakewood-Amedex Biotherapeutics (NASDAQCM:LABT) with a Buy recommendation. This initiation represents the primary analyst activity for the company on this date.Prior to the rating action, the s
- RTTNews · Sep 21, 2:26 AM EDTLakewood-Amedex Secures IRB Approval To Begin Nu-3 Phase 2a Study In Infected Diabetic Foot Ulcer(RTTNews) – Lakewood-Amedex Biotherapeutics Inc. (LABT), a clinical-stage biotechnology company announced that it has obtained central and all site Institutional Review Board (IRB) approvals and confirmed clinical trial site readiness to commence its Phase 2a clinical trial evalu
- RTTNews · Jul 22, 11:09 PM EDTTop Biotech Gainers: ZCMD Surges 190%, LABT Advances On Nu-3 Progress, ARWR Hits The Targets(RTTNews) – Today's top gainers in the healthcare sector include Zhongchao, surging more than 190%; Lakewood-Amedex, advancing on positive antimicrobial drug progress; Arrowhead, delivering encouraging severe hypertriglyceridemia trial results; and LB Pharma, accelerating the LB-
- RTTNews · Jul 22, 9:13 AM EDTLakewood-Amedex Highlights Nu-3 Resistance Data In Support Of National Action Plan; Stock Up(RTTNews) – Lakewood-Amedex Biotherapeutics Inc. (LABT) has announced new findings on its antimicrobial candidate Nu-3, underscoring its potential role in combating antibiotic resistance as outlined by the Presidential Advisory Council's National Action Plan.
- RTTNews · May 18, 9:56 AM EDTLakewood-Amedex Provides Progress Update Of Nu-3 In Diabetic Foot Ulcers; Stock Down(RTTNews) – Lakewood-Amedex Biotherapeutics Inc. (LABT), a clinical-stage biotechnology company, announced progress in manufacturing and formulation for its lead investigational drug candidate, Nu-3, being developed to treat infected diabetic foot ulcers.
- RTTNews · Apr 24, 7:15 AM EDTLakewood-Amedex Debuts On Nasdaq Under LABT; Stock Soar(RTTNews) – Lakewood-Amedex Biotherapeutics Inc. (LABT), a clinical-stage biotech focused on antimicrobial resistance, began trading yesterday on the Nasdaq Capital Market through a direct listing. Shares opened at $8.00, marking the company's entry into U.S. public markets under
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Lakewood-Amedex Biotherapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.